Reliable. Secure. Since 2012. Exchange Crypto Sign up to get a trading fee discount!
West Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com
West syndrome, also known as Infantile spasms, is a severe neurological disorder that affects infants and young children, characterized by early onset seizures, usually between 4-7 months of age, which can be flexor, extensor or flexor-extensor spasms, abnormal brain activity seen on an EEG and a poor prognosis for seizure control and intellectual development. The cause of West syndrome can be prenatal, perinatal, or postnatal. It can be classified as symptomatic groups that are considered the consequences of a known or suspected central nervous system disorder. Cryptogenic groups are presumed to be symptomatic, but the etiology is not known. Idiopathic forms, having no underlying cause other than a possible hereditary predisposition, are not recognized for West syndrome in the current International Classification. Other conditions that may be considered in the diagnosis of West syndrome include epilepsy with mental retardation, other epileptic and epileptiform encephalopathies, benign myoclonus of early infancy, and myoclonic-astatic epilepsy. The outlook for infants with West syndrome is poor, with only 14% of infants with symptomatic West syndrome having normal or borderline-normal cognitive development compared with 28-50% of infants with idiopathic infantile spasms. Some factors such as idiopathic or cryptogenic etiology, the onset of seizures after four months, absence of atypical spasms and partial seizures, absence of asymmetrical EEG abnormalities, early treatment, and an excellent response to treatment can predict a more favorable outcome. Infants with symptomatic infantile spasms are more likely to develop autism spectrum disorders than those with cryptogenic or idiopathic spasms. Steroids and anti-seizure medications are the most commonly used treatments, with the steroid ACTH sometimes being injected into the muscles.
• The incidence rate of infantile spasms in the USA is estimated to be 2.5-6.0 cases per 10,000 live births.
• Its prevalence rate is 1.5-2.0 cases per 10,000 children aged ten years or younger.
Thelansis’s “West Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential West Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of West Syndrome across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
West Syndrome Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: West Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033